GNRH AGONIST TEST

促性腺激素释放激素激动剂测试

• 批准号: 7604773
• 负责人: ROBERT L ROSENFIELD
• 金额: $ 0.93万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604773
• 关键词: Agonist; Back; Biological Assay; Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Delayed Puberty; Diagnosis; Diagnostic; Disease; Dose; Funding; Generations; Gonadal Steroid Hormones; Gonadotropins; Grant; Hormonal; Injection of therapeutic agent; Institution; Lead; Leuprolide Acetate; Outcome Measure; Pharmaceutical Preparations; Precocious Puberty; Puberty; Purpose; Research; Research Personnel; Resources; Scientific Advances and Accomplishments; Sleep; Source; Testing; United States National Institutes of Health; novel diagnostics; relisorm L; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To test the overall hypothesis that the hormonal responses to injection of a challenge dose of GnRH agonist (GnRHag) will distinguish among disorders of puberty as well as a sleep test. Specifically, we will test the hypotheses that the response to injection of the GnRH agonist leuprolide acetate will distinguish among the causes of precocious puberty and among the causes of delayed puberty as well as a hormonal sleep test. Obstacles to making a timely diagnosis of disorders of puberty exist: 1) manufacturing cut-backs for low-profit drugs lead to frequent unavailability of natural GnRH (Factrel) for testing purposes, 2) childhood norms and diagnostic criteria have not been established for the current generation of highly sensitive and specific gonadotropin and sex steroid assays, and 3) scientific advances have led to potential new diagnostic outcome measures. This project compares children with disorders of puberty with healthy childhood controls. Primary outcome measures are the mean LH response to sleep in comparison to the LH peak response to the GnRHag leuprolide acetate.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 为了检验总体假设，即注射激发剂量的GnRH激动剂（GnRHag）的激素反应将区分青春期疾病和睡眠试验。 具体而言，我们将检验以下假设：对注射GnRH激动剂醋酸亮丙瑞林的反应将区分性早熟的原因和青春期延迟的原因以及激素睡眠试验。及时诊断青春期疾病的障碍存在：1）低利润药物的生产削减导致天然GnRH（Factrel）经常无法用于测试目的，2）尚未为当前一代高度敏感和特异性促性腺激素和性类固醇检测建立儿童规范和诊断标准，3）科学进步导致潜在的新诊断结果措施。该项目将青春期发育障碍儿童与健康儿童对照组进行比较。 主要结局指标是与GnRHag醋酸亮丙瑞林的LH峰值反应相比，睡眠的平均LH反应。